Evolus (NASDAQ:EOLS – Get Rating) will post its quarterly earnings results after the market closes on Tuesday, May 10th. Analysts expect Evolus to post earnings of ($0.46) per share for the quarter. Evolus has set its FY 2022 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.
Evolus (NASDAQ:EOLS – Get Rating) last released its quarterly earnings data on Thursday, March 3rd. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.19. The firm had revenue of $34.66 million for the quarter, compared to analysts’ expectations of $34.70 million. Evolus had a negative net margin of 46.96% and a negative return on equity of 60.65%. On average, analysts expect Evolus to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Evolus stock opened at $11.41 on Tuesday. The company has a current ratio of 3.10, a quick ratio of 3.07 and a debt-to-equity ratio of 0.87. Evolus has a 1-year low of $5.06 and a 1-year high of $14.30. The firm has a 50-day moving average of $10.77 and a 200-day moving average of $8.26.
In other news, CMO Crystal Muilenburg sold 6,495 shares of the business’s stock in a transaction that occurred on Tuesday, March 8th. The stock was sold at an average price of $9.73, for a total value of $63,196.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Moatazedi sold 37,972 shares of the firm’s stock in a transaction that occurred on Tuesday, March 8th. The shares were sold at an average price of $9.73, for a total value of $369,467.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,571 shares of company stock valued at $503,592. 7.60% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of EOLS. BlackRock Inc. boosted its stake in Evolus by 2.5% in the 4th quarter. BlackRock Inc. now owns 2,226,921 shares of the company’s stock worth $14,498,000 after purchasing an additional 54,531 shares in the last quarter. Nuveen Asset Management LLC lifted its stake in shares of Evolus by 13.1% in the fourth quarter. Nuveen Asset Management LLC now owns 917,031 shares of the company’s stock worth $5,145,000 after buying an additional 106,052 shares in the last quarter. D. E. Shaw & Co. Inc. grew its holdings in shares of Evolus by 6.4% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 700,306 shares of the company’s stock valued at $4,559,000 after buying an additional 42,087 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Evolus by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 588,800 shares of the company’s stock valued at $3,833,000 after buying an additional 14,363 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Evolus by 3.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 301,008 shares of the company’s stock valued at $1,960,000 after acquiring an additional 9,641 shares in the last quarter. Hedge funds and other institutional investors own 36.94% of the company’s stock.
About Evolus (Get Rating)
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
- Get a free copy of the StockNews.com research report on Evolus (EOLS)
- Tractor Supply Stock Should Plow Ahead
- MarketBeat Podcast: Investing In Innovation, Robotics, AI and Healthcare
- GitLab Stock is Trying to Put in a Bottom Here
- Saia Growth Accelerates But It May Not Matter
- It’s Time to Book an Appointment for Teladoc Stock
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.